...
....
Pharmaceutical
Biotechnology

> See specialized channels
Medical Devices & Diagnostics
> See specialized channels
Industrial
Biotechnology
> See specialized channels


  Join us

  Follow us on Twitter   Join our LinkedIn Group   Our Blog

Biotech News App
Provides access to the latest biotech press releases ...more

Android_Logo App Store RIM_Logo_small

Media Partnership:
Want to have your RSS feed integrated on our website? Contact us
RSS Feeds RSS Feeds
JoomlaWatch Stats 1.2.9 by Matej Koval
For Editors
Sign up for press releases
For Companies
Sign up for our newsletter
Back to PRESS RELEASES - 

Erasmus University Medical Centre in Rotterdam Adopts Automated Target Enrichment Solution from Roche NimbleGen and Caliper Life Sciences for 3,000 Sample Exome Study

| Print |
Tuesday, 06 September 2011 14:00 (UTC + 2)

Roche_Logo

Madison, WI, USA, September 6, 2011 / B3C newswire / - The Genetic Laboratory of the Department of Internal Medicine at Erasmus University Medical Centre in Rotterdam has adopted the combined automated target enrichment solution from Roche (SIX: RO, ROG; OTCQX: RHHBY) and Caliper Life Sciences. This optimized solution is being used in a new phase of a large human epidemiological cohort, the Rotterdam Study, for automating the capture of >3,000 samples for next-generation sequencing.

The Rotterdam Study is a large prospective, single-center, population-based cohort study in a suburb of Rotterdam, The Netherlands, and includes 15,000 participants of 45 years or more who have been followed since 1990. The aim of the study is to characterize and analyze age-related disorders and their risk factors. The study is coordinated by the department of Epidemiology of the Erasmus University Medical Center in Rotterdam. To date, the Rotterdam Study has resulted in >1,000 peer-reviewed scientific publications and >100 PhD theses.

A major focus of the Rotterdam Study has been the identification of genetic risk factors for age-related disorders such as osteoporosis, cardiovascular disease, Alzheimer disease, and type 2 diabetes. To accommodate the vast amounts of data, a Genome Wide Association Study (GWAS) database was established in 2007 by the Genetic Laboratory at the Department of Internal Medicine. By using Roche’s exome capture product, NimbleGen SeqCap EZ Exome Library, combined with Caliper Life Sciences Sciclone NGS Workstation, the Erasmus MC team will now look to discover more data with an automated exome sequencing sample preparation solution. In implementing this optimized automated solution using multiplex protocols for capture and sequencing, they are anticipating to complete this phase of the project shortly in processing and sequencing 3,000 samples in the next 3-4 months.

“The automated Roche capture platform was in our case the most optimal solution to analyse these thousands of DNA samples,” stated Prof Uitterlinden, Head of the Genetic Lab. “It will bring the large database we have been creating over the years of the Rotterdam Study to a new and deeper level of genetic resolution, hopefully leading to further exciting discoveries in the field of complex genetics.”

This exome sequencing study is being done in collaboration with the other members of the CHARGE consortium who are involved in a similar study in their respective cohorts. The study takes place within the framework of the NGI-sponsored Netherlands Consortium for Healthy Ageing (NCHA; www.healthy-ageing.nl ). In autumn 2011 the first data are expected to be available for analysis.

“We’re extremely excited to see our technologies selected for use in the Rotterdam Study,” said Frank Pitzer, CEO of Roche NimbleGen. “This sample cohort has been used to significantly advance our knowledge of age-related disorders and we are honored to have our technology adopted for use in such a comprehensive and well-organized study.”

For more information about Roche NimbleGen, please visit www.nimblegen.com

 

About Roche
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2009, Roche had over 80’000 employees worldwide and invested almost 10 billion Swiss francs in R&D. The Group posted sales of 49.1 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.

 

About Erasmus MC, University Medical Center in Rotterdam
Erasmus MC is the largest and most authoritative scientific University Medical Center in the Netherlands. Almost 13,000 staff members work within the core tasks of patient care, education, and scientific research on the continuous improvement and enforcement of individual patient care and social healthcare. They develop high-level knowledge, pass this on to future professionals, and apply it in everyday patient care. Over the next five years, Erasmus MC desires to grow into one of the best medical institutes in the world. Erasmus MC is part of the Dutch Federation of University Medical Centers (NFU): www.nfu.nl. For more information: www.erasmusmc.nl.


For life science research only. Not for use in diagnostic procedures.
NIMBLEGEN and SEQCAP are trademarks of Roche.
All other product names and trademarks are the property of their respective owners.


For further information about Roche please contact:

Roche Diagnostics
Dr. Burkhard Ziebolz
Phone: +49 8856 604830
Email: This e-mail address is being protected from spambots. You need JavaScript enabled to view it

Roche NimbleGen
Kary Staples
Phone: +1 608 218 7623
Email: This e-mail address is being protected from spambots. You need JavaScript enabled to view it